Searle & Co’s Progenics Pharmaceuticals Inc PGNX Stock Holding History

Searle & Co’s Portfolio PGNX Stock Details PGNX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q1	–	Sell	-14,500	Closed	-$86K	–	135
2017 Q4	$86K	Hold	14,500	–	–	0.05%	128
2017 Q3	$107K	Sell	14,500 -36,500	-72%	-$232K	0.07%	124
2017 Q2	$346K	Hold	51,000	–	–	0.24%	97
2017 Q1	$481K	Buy	+51,000	New	+$509K	0.34%	83
2016 Q4	–	Sell	-105,000	Closed	-$726K	–	116
2016 Q3	$726K	Buy	+105,000	New	+$635K	0.63%	54
2016 Q2	–	Sell	-105,000	Closed	-$463K	–	97
2016 Q1	$463K	Buy	105,000 +45,000	+75%	+$200K	0.43%	66
2015 Q4	$349K	Sell	60,000 -15,000	-20%	-$98.3K	0.33%	81
2015 Q3	$429K	Sell	75,000 -2,500	-3%	-$19.2K	0.44%	67
2015 Q2	$578K	Sell	77,500 -2,500	-3%	-$15.1K	0.48%	59
2015 Q1	$478K	Buy	+80,000	New	+$503K	0.41%	65

Other funds holding PGNX

Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

EAM

Eagle Asset Management St Petersburg, Florida $19.6B AUM 41.58% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

CTA

Carillon Tower Advisers St. Petersburg, Florida $16.4B AUM 64.75% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

AAP

Ardsley Advisory Partners Stamford, Connecticut $960M AUM 207.76% 1-Year Est. Return

Pinnacle Associates New York $7.78B AUM 45.07% 1-Year Est. Return

Searle & Co's PGNX Position: Q1 2018 in Review

Searle & Co sold out of Progenics Pharmaceuticals Inc (PGNX) in Q1 2018, closing a stake of 14,500 shares — an estimated $86K sold.

Searle & Co first reported a position in PGNX in Q1 2015 and held it in 10 quarters. The position peaked at $726K in Q3 2016. 152 funds tracked by Wall St. Rank hold PGNX as of Q1 2018.

Searle & Co reported no remaining Progenics Pharmaceuticals Inc position as of Q1 2018 after selling out during the quarter.
Searle & Co sold 14,500 Progenics Pharmaceuticals Inc shares in Q1 2018, an estimated $86K.
Searle & Co first reported a position in Progenics Pharmaceuticals Inc in Q1 2015 and held it in 10 quarters.
Searle & Co's Progenics Pharmaceuticals Inc position peaked at $726K in Q3 2016.
152 funds tracked by Wall St. Rank held Progenics Pharmaceuticals Inc as of Q1 2018.

Based on Searle & Co's 13F filing for Q1 2018, filed 25 Apr 2018.